Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs - Wikidata - wikimedia - TriplyDB

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs

http://www.wikidata.org/entity/Q28547522

about

IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.Feedback activation of AMPK-mediated autophagy acceleration is a key resistance mechanism against SCD1 inhibitor-induced cell growth inhibition.Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs.Correction: Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models.

P2860

Q28555124-0A1B1E22-14FF-4558-B583-CC6AF8E4192A Q38706993-83BFBBFE-AAAB-4AC8-998A-15127FA6DD8E Q41007633-E5A83858-CEBF-4756-A8DB-7889A703B997 Q42116442-F838FFF0-E6A1-41DB-9D51-256496CDA134 Q42377374-03178436-319A-4749-BC59-6102F069B33D Q49547317-AC62A91C-CCC9-4764-9A8E-F7A1AC4D0F46

P2860

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs

http://www.wikidata.org/entity/Q28547522

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

Selective Targeting of CTNBB1- ...... Combinations of Existing Drugs

@ast

Selective Targeting of CTNBB1- ...... Combinations of Existing Drugs

@en

Selective Targeting of CTNBB1- ...... Combinations of Existing Drugs

@nl

type

label

Selective Targeting of CTNBB1- ...... Combinations of Existing Drugs

@ast

Selective Targeting of CTNBB1- ...... Combinations of Existing Drugs

@en

Selective Targeting of CTNBB1- ...... Combinations of Existing Drugs

@nl

prefLabel

Selective Targeting of CTNBB1- ...... Combinations of Existing Drugs

@ast

Selective Targeting of CTNBB1- ...... Combinations of Existing Drugs

@en

Selective Targeting of CTNBB1- ...... Combinations of Existing Drugs

@nl

P1433

Q28547522-C48D1C0C-AE0B-4467-8397-185943B016DB

P1476

Q28547522-B6B05C3F-A6A7-4B0B-ABF7-D44B1B828465

P2093

Q28547522-1EEB139F-0E3F-4D77-A26E-024D180DE391

Q28547522-2BEBF3CD-000A-4324-AB7E-46F00C62721C

Q28547522-3A596E82-5DF2-4282-A868-24E4DAF91682

Q28547522-527F967B-979A-42EF-B794-4F2C361A278C

Q28547522-53D1B3C9-FD42-4E6A-B802-F32639AF8014

Q28547522-7C373D00-BADF-4302-8E97-D3EC0CD14CDB

Q28547522-A05E0C55-7525-4BC7-B2DB-607396D76477

Q28547522-DCDD793D-3198-45E1-9DCF-EAD0EE297E1D

Q28547522-E0F3C81A-790A-4E27-908D-42E9731A1FE8

P2860

Q28547522-0415732B-8FBC-4FF5-B1C4-159DBE5C7D65

Q28547522-0A220990-99A4-43D1-A37F-64A1290E5D88

Q28547522-1417BBFD-5546-444F-B94C-C1359FC4F3C4

Q28547522-175F9D1F-593B-49D4-8B60-5C2AA8A883B2

Q28547522-1A08F35B-8FDC-44B6-88B7-B1BE29F5D47B

Q28547522-20519C59-8AFC-4318-A6FD-3AA24669C5AC

Q28547522-208231B1-219A-45AA-976A-0771AECA9748

Q28547522-20E75530-C536-462F-ACB3-4BF8DE3E2472

Q28547522-2DE862FE-9E51-4149-9B5C-0F3F906DAD7F

Q28547522-34787873-AAEF-4B71-9CEC-7B3901FBF17C

P304

Q28547522-BC4CA566-012B-464E-B5D4-EF27D4594F34

P31

Q28547522-E7DBA136-E3DD-4EDC-87F3-B79CFE498D7C

P356

Q28547522-EB7927B0-4D88-40A2-9EEB-EE13D333BB0B

P407

Q28547522-C70DD3D4-D7BC-43C4-B51D-6A93FB86A9C4

P433

Q28547522-439293BF-165B-4B7F-9AC3-94A54040B82A

P478

Q28547522-D7A736C3-DF6D-4777-A840-BB30CA0A3484

P577

Q28547522-15C92EB8-D2E2-4698-A806-10DF51EC61E0

P698

Q28547522-F0AE0518-5B77-4083-BCC6-CA6DFCA194E5

P932

Q28547522-08667BBC-723E-4813-AA59-32F2DCE58CDF

P356

JOURNAL.PONE.0125021

P1433

P1476

Selective Targeting of CTNBB1- ...... Combinations of Existing Drugs

@en

P2093

Antoon M van Doornmalen

http://www.w3.org/2001/XMLSchema#string

Guido J R Zaman

http://www.w3.org/2001/XMLSchema#string

Jeroen A D M de Roos

http://www.w3.org/2001/XMLSchema#string

Jill A P Spijkers-Hagelstein

http://www.w3.org/2001/XMLSchema#string

Joost C M Uitdehaag

http://www.w3.org/2001/XMLSchema#string

Jos de Man

http://www.w3.org/2001/XMLSchema#string

Judith R F de Vetter

http://www.w3.org/2001/XMLSchema#string

Martine B W Prinsen

http://www.w3.org/2001/XMLSchema#string

Rogier C Buijsman

http://www.w3.org/2001/XMLSchema#string

P2860

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use

The druggable genome

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Systematic identification of genomic markers of drug sensitivity in cancer cells

P304

e0125021

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0125021

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26018524

http://www.w3.org/2001/XMLSchema#string

P932

4446296

http://www.w3.org/2001/XMLSchema#string